Global Information
회사소개 | 문의 | 위시리스트

세계의 뇌종양 치료 시장(-2023년)

Brain Tumor Therapeutics: Global Markets to 2023

리서치사 BCC Research
발행일 2018년 12월 상품 코드 762927
페이지 정보 영문 161 Pages
가격
US $ 5,500 ₩ 6,571,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,600 ₩ 7,886,000 PDF by E-mail (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,920 ₩ 9,463,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 9,504 ₩ 11,356,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 뇌종양 치료 시장(-2023년) Brain Tumor Therapeutics: Global Markets to 2023
발행일 : 2018년 12월 페이지 정보 : 영문 161 Pages

세계의 뇌종양 치료제 시장 규모는 2018년 11억 달러에서 2023년까지 20억 달러로 확대될 것으로 예측되며, 2018-2023년간 12.9%의 연평균 성장률(CAGR)이 전망됩니다.

세계의 뇌종양 치료(Brain Tumor Therapeutics) 시장에 대해 조사했으며, 세계 시장 개요, 국가별 데이터와 분석, 주요 시장 성장 촉진요인과 억제요인, 지역적인 역학 및 주요 기업 개요 등을 제공합니다.

제1장 서론

제2장 요약과 하이라이트

제3장 질환 배경과 개요

  • 서론
  • 질환 배경
  • 뇌종양 진단
  • 뇌종양 재발과 관리
  • 치료법

제4장 시장 역학

  • 서론
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 현재 시장 동향

제5장 시장 분석 : 치료법별

  • 서론
  • 화학요법
  • 표적요법
  • 면역요법

제6장 시장 분석 : 환자 연령별

  • 서론
  • 개요
  • 치료 선택사항
  • 시장 개요
  • 시장 규모와 예측

제7장 시장 분석 : 최종사용자별

제8장 시장 분석 : 지역별

  • 서론
  • 북미
  • 유럽
  • 아시아태평양
  • 기타

제9장 신기술과 향후 동향

  • 서론
  • 암백신
  • 나노 의약품
  • 줄기세포요법
  • 광선역학요법
  • 집속초음파요법
  • 레디오믹스(Radiomics) 및 파소믹스(Pathomics)
  • CRISPR
  • 인공지능(AI)
  • 게노믹스 및 맞춤형 의료의 진보

제10장 뇌종양 치료제의 임상 연구

  • 서론
  • 의약품 개발 프로세스
  • 연구 계획
  • 임상시험 및 실험적 치료

제11장 특허 리뷰

제12장 경쟁 상황과 시장 전략

  • 서론
  • 주요 기업과 시장 점유율 분석
  • 주요 기업이 채용하는 시장 전략
  • 신규 개발
  • Porter's Five Forces 분석

제13장 규제 및 의료비 상환 상황

  • 서론
  • 의약품 개발 규제
  • 의료비 상환 상황

제14장 기업 개요

부록 : 두문자어

BBC Research 소개

KSM 19.01.11

List of Tables

  • Summary Table: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023
    • Table 1: WHO Grading of Brain Tumors
    • Table 2: WHO Grading of Select Brain Tumors
    • Table 3: Survival Rates for Common Adult Brain and Spinal Cord Tumors, 2017
    • Table 4: Brain Structures and Functions
    • Table 5: WHO Classification of Brain Tumors, 2016
    • Table 6: Karnofsky Performance Scale
    • Table 7: Specific Types of Brain Tumor Metastasis
    • Table 8: Parts of the Brain Related to Major Cognitive Functions
    • Table 9: Timeline of Significant Developments in Radiotherapy, 1898-2006
    • Table 10: Rare/Orphan Drug Criteria: Selected Regulatory Organizations
    • Table 11: Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2023
    • Table 12: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
    • Table 13: Dosage and Administration of Temozolomide for Brain Tumors
    • Table 14: Current Brain Tumor Clinical Trials: Temozolomide
    • Table 15: Current Brain Tumor Clinical Trials involving Lomustine
    • Table 16: Current Brain Tumor Clinical Trials involving Carmustine
    • Table 17: PCV Regimen: Brain Tumor Chemotherapy
    • Table 18: Global Market for Brain Tumor Chemotherapy, by Region, Through 2023
    • Table 19: FDA Approved Targeted Therapeutic Agents for Brain Tumors
    • Table 20: Monoclonal Antibodies
    • Table 21: Small Molecule Monoclonal Antibodies
    • Table 22: Current Brain Tumor Clinical Trials involving Bevacizumab
    • Table 23: Current Brain Tumor Clinical Trials involving Everolimus
    • Table 24: Global Market for Brain Tumor Targeted Therapy, by Region, Through 2023
    • Table 25: Current Brain Tumor Clinical Trials: Immunotherapy
    • Table 26: Global Market for Brain Tumor Therapeutics, by Patient Age, Through 2023
    • Table 27: Hereditary Factors: Pediatric Brain Tumors
    • Table 28: Global Market for Adult Brain Tumor Therapeutics, by Region, Through 2023
    • Table 29: Global Market for Pediatric Brain Tumor Therapeutics, by Region, Through 2023
    • Table 30: Global Market for Brain Tumor Therapeutics Market, by End User, Through 2023
    • Table 31: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, Through 2023
    • Table 32: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, Through 2023
    • Table 33: Global Market for Brain Tumor Therapeutics in Universities, by Region, Through 2023
    • Table 34: Global Market for Brain Tumor Therapeutics , by Region, Through 2023
    • Table 35: North American Market for Brain Tumor Therapeutics, by Country, Through 2023
    • Table 36: European Market for Brain Tumor Therapeutics, by Country, Through 2023
    • Table 37: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, Through 2023
    • Table 38: Drug Development
    • Table 39: Selected Current Phase I Brain Tumor Clinical Trials
    • Table 40: Selected Current Phase II Brain Tumor Clinical Trials
    • Table 41: Selected Current Phase III Brain Tumor Clinical Trials
    • Table 42: Patent Review of Novel Compounds and Drug Delivery in Brain Tumors, February 2017 to August 2018
    • Table 43: Patent Review of Therapeutic Agents for Brain Tumors, January 2017 to August 2018
    • Table 44: Patent Review of Combination Therapies in Brain Tumors, September 2017 to September 2018
    • Table 45: Patent Review of Immunotherapies for Brain Tumors, December 2016 to July 2018
    • Table 46: Patent Review of Diagnosis and Biomarkers in Brain Tumors, January 2017 to September 2018
    • Table 47: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
    • Table 48: Current Orphan Drug Designations for Brain Tumors
    • Table 49: Bristol-Myers Squibb: Revenue 2016 and 2017
    • Table 50: Bristol-Myers Squibb: Brain Tumor Pharmaceuticals
    • Table 51: Opdivo Approvals, 2017
    • Table 52: F. Hofmann-La Roche: Revenue 2016 and 2017
    • Table 53: F. Hofmann-La Roche: Brain Tumor Pharmaceutical Drugs
    • Table 54: Merck & Co., Inc.: Revenue 2016 and 2017
    • Table 55: Merck & Co., Inc.: Brain Tumor Pharmaceutical Drugs
    • Table 56: NextSource Biotechnology LLC: Brain Tumor Therapeutics
    • Table 57: Novartis: Revenue 2016 and 2017
    • Table 58: Novartis: Brain Tumor Pharmaceuticals
    • Table 59: Important Acronyms Related to Brain Tumor Therapeutics Used in This Report

List of Figures

  • Summary Figure: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023
    • Figure 1: Percentage Share of Global Cancer Incidence, by Type, 2018
    • Figure 2: Percentage Share of Global Cancer Incidence, by Region, 2018
    • Figure 3: Hallmarks of Cancer
    • Figure 4: Five Year Relative Survival at Diagnosis, by Stage, 2014-2018
    • Figure 5: Goals of Surgical Treatment for Brain Tumors
    • Figure 6: Global Expenditures on Oncology Drugs, by Country/Region, 2013-2017
    • Figure 7: Projected Global Expenditures on Oncology Drugs, by Country/Region, 2020
    • Figure 8: Global Market for Brain Tumor Therapeutics, by Therapy Type, 2017-2023
    • Figure 9: Global Market for Brain Tumor Chemotherapy, by Region, 2017-2023
    • Figure 10: Targeted Therapy Types
    • Figure 11: Global Market for Brain Tumor Targeted Therapy, by Region, 2017-2023
    • Figure 12: Global Market for Brain Tumor Therapeutics, by Patient Age, 2017-2023
    • Figure 13: Percentage Share of Common Adult Brain Tumor Incidence, by Type, 2017
    • Figure 14: Percentage Share of Common Pediatric Brain Tumor Incidence, 2017
    • Figure 15: Differences: Adult and Pediatric Brain Tumors
    • Figure 16: Etiology: Pediatric Brain Tumors
    • Figure 17: Global Market for Adult Brain Tumor Therapeutics, by Region, 2017-2023
    • Figure 18: Global Market for Pediatric Brain Tumor Therapeutics, by Region, 2017-2023
    • Figure 19: Global Market for Brain Tumor Therapeutics in Hospitals, by Region, 2017-2023
    • Figure 20: Global Market for Brain Tumor Therapeutics in Research Institutes, by Region, 2017-2023
    • Figure 21: Global Market for Brain Tumor Therapeutics in Universities, by Region, 2017-2023
    • Figure 22: Global Incidence of Brain Tumors, 2018-2040
    • Figure 23: Global Market for Brain Tumor Therapeutics Market, by Region, 2017-2023
    • Figure 24: North American Incidence of Brain Tumors, 2018-2040
    • Figure 25: North American Market for Brain Tumor Therapeutics, 2017-2023
    • Figure 26: North American Market for Brain Tumor Therapeutics, by Country, 2017-2023
    • Figure 27: European Incidence of Brain Tumors, 2018-2040
    • Figure 28: European Market for Brain Tumor Therapeutics, 2017-2023
    • Figure 29: European Market for Brain Tumor Therapeutics, by Country, 2017-2023
    • Figure 30: Asia-Pacific Incidence of Brain Tumors, 2018-2040
    • Figure 31: Asia-Pacific Market for Brain Tumor Therapeutics, 2017-2023
    • Figure 32: Asia-Pacific Market for Brain Tumor Therapeutics, by Country, 2017-2023
    • Figure 33: ROW Market for Brain Tumor Therapeutics, 2017-2023
    • Figure 34: Pharmaceutical Drug Development
    • Figure 35: Current Clinical Trials, by Phase, 2018
    • Figure 36: Major Market Players Share in Brain Tumor Therapeutics Market, 2017
    • Figure 37: NIH Funding for Brain Cancer R&D, 2016-2018
    • Figure 38: R&D Expenditure of Top 3 Players in Brain Tumor Therapeutics, 2017
    • Figure 39: Bargaining Power of Buyers in the Brain Tumor Therapeutics Industry
    • Figure 40: Bargaining Power of Suppliers in the Brain Tumor Therapeutics Industry
    • Figure 41: Threat from New Entrants in the Brain Tumor Therapeutics Industry
    • Figure 42: Threat from Substitutes in the Brain Tumor Therapeutics Industry
    • Figure 43: Market Competition in the Brain Tumor Therapeutics Industry
    • Figure 44: Pharmaceutical Regulatory Pathways in the U.S and Europe
    • Figure 45: Bristol-Myers Squibb: Net Sales, by Region/Country, 2017
    • Figure 46: Bristol-Myers Squibb: R&D Expenditure, 2016 and 2017
    • Figure 47: Roche Top 5 Pharmaceutical Drugs, by Sales Revenue, 2017
    • Figure 48: Avastin: Sales Revenue, 2016 and 2017
    • Figure 49: F. Hofmann-La Roche: Revenue Share, by Business Segment, 2017
    • Figure 50: F. Hofmann-La Roche: Revenue, by Region, 2015-2017
    • Figure 51: Roche Product Pipeline, by Disease Area, 2017
    • Figure 52: Novartis: Net Sales, by Division, 2017
    • Figure 53: Novartis: Net Sales, by Region, 2017

Report Highlights:

The global market for brain tumor therapeutics should grow from $1.1 billion in 2018 to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% for the period of 2018-2023.

Chemotherapy segment of brain tumor therapeutics market should grow from $771.3 million in 2018 to reach $1.3 billion by 2023 at a CAGR of 11.1% for the period of 2018-2023.

Targeted therapy segment of brain tumor therapeutics market should grow from $297.2 million in 2018 to reach $652.8 million by 2023 at a CAGR of 17.0% for the period of 2018-2023.

Report Scope:

This report provides an overview of the current and future global market potential for brain tumor therapeutics. It provides a detailed analysis and information about conventional treatment options, ongoing market trends and the future direction of the market with respect to brain tumor therapy.

Inclusions

  • The report covers a detailed background of the disease state, along with epidemiological and demographic data, market segmentation by therapy (chemotherapy and targeted therapy), age group of patients (adult and pediatric brain tumors), end users (hospitals, cancer research institutes and medical universities) and a detailed regional market analysis including North America, Europe, Asia-Pacific and the rest of the world.
  • The report provides information on newer treatment opportunities and cutting-edge research on therapeutics for brain tumors. It covers various types of treatment used in the field of neuro-oncology: surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy.
  • A detailed analysis of agents used in the market for chemotherapy, immunotherapy and targeted therapy, as well as a pipeline analysis of newer molecules and therapeutics is covered in the report.
  • A comprehensive analysis of market dynamics in the industry and current market trends are described in the report, along with the competitive landscape and discussion about key market players in the field of brain tumor therapeutics, where market strategies of these players are studied and described. The report includes a patent analysis of brain tumor therapeutics.
  • The report concludes with company profiles of key players in the development and commercialization of brain tumor therapeutics.
  • A separate chapter on emerging trends and breakthrough technologies in the field of neuro-oncology has been included in this report.

Exclusions

Excluded from this report are the market size for equipment used in radiotherapy, surgical equipment and supplies and market size for drugs used for the symptomatic management of cancer (anti-epileptics, anti-emetics and hormonal medications). This report also excludes market size for immunotherapy. This is not a proven treatment for brain tumors and is currently being developed in research and clinical trials.

Market values are provided for 2017 as base year, 2018 and forecast through 2023.Estimated values are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

  • 20 data tables and 40 additional tables
  • Comprehensive overview of the global market for brain tumor therapeutics within the pharmaceutical industry
  • Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Country specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
  • Impact analysis of major drivers and restraints, and regional dynamics of the global brain tumor therapeutics markets and current trends within the industry
  • Company profiles of prominent players in the market, including Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis International AG

Table of Contents

Chapter 1: Introduction

  • Scope of Report
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Information Sources and Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • Key Findings

Chapter 3: Disease Background and Overview

  • Introduction
    • What is Cancer?
    • Cancer Drivers
    • Cancer Staging
  • Disease Background
    • Brain Tumor Statistics
    • Human Brain Function
    • Causes of Tumor Development
    • Mechanism of Tumorigenesis
    • Types and Classification of Brain Tumors
  • Diagnosis of Brain Tumors
    • Magnetic Resonance Imaging (MRI)
    • Magnetic Resonance Spectroscopy (MRS)
    • Tissue Sampling/Biopsy/Surgical Removal of Tumor
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET) or PET-CT Scan
    • Cerebral Arteriogram
    • Lumbar Puncture or Spinal Tap
    • Myelogram
    • Molecular Testing
    • Neurological, Vision and Hearing Tests
    • Neurocognitive Assessment
    • Electroencephalography (EEG)
    • Evoked Potentials
  • Recurrence of Brain Tumors and Management
    • Brain Tumor Metastases and Management
    • Cognitive Challenges
    • Pain Management
  • Treatment Modalities
    • Surgery
    • Neurosurgery
    • Emerging Treatments in Neurosurgery
    • Radiotherapy
    • New and Emerging Treatments in Neuro-radiotherapy
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy

Chapter 4: Market Dynamics

  • Introduction
  • Market Drivers
    • Increasing Global Incidence of Brain Cancer
    • Early Cancer Detection
    • Research Initiatives
    • R&D Collaborations
    • Increase in Oncology Spending
    • Accelerated Approvals for Drugs Used in Rare Diseases
  • Market Restraints
    • Lack of Effective Treatment Options for Brain Tumors
    • High Cost
    • Low Screening
  • Current Market Trends
    • Immunotherapy
    • Combination Therapy
    • MRI-Guided Laser Surgery
    • Palliative Therapy
    • 3D Radiation Therapy
    • Precision Medicine and Companion Diagnostics
    • Polymer Wafer Implants
    • Tumor Treating Fields (TTF)

Chapter 5: Market Breakdown by Therapy

  • Introduction
  • Chemotherapy
    • Overview
    • Principle of Chemotherapy
    • BBB and Chemotherapy
    • Chemotherapeutic Agents
    • Side Effects of Chemotherapy
    • New Developments
    • Market Overview
    • Market Size and Forecast
  • Targeted Therapy
    • Introduction
    • Precision Medicine in Cancer
    • Types and Methods of Targeted Therapy
    • Drug Delivery Systems for Targeted Therapeutics
    • FDA-Approved Targeted Therapeutics
    • New Developments
    • Market Overview
    • Market Size and Forecast
  • Immunotherapy
    • Introduction
    • Immunotherapeutic Agents
    • New Developments
    • Market Overview

Chapter 6: Market Breakdown by Patient Age

  • Introduction
  • Overview
  • Treatment Options
  • Market Overview
  • Market Size and Forecast

Chapter 7: Market Breakdown by End User

Chapter 8: Market Breakdown by Region

  • Introduction
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 9: Emerging Technologies and Future Trends

  • Introduction
  • Cancer Vaccines
  • Nanomedicine
  • Stem Cell Therapy
  • Photodynamic Therapy
  • Focused Ultrasound Therapy
  • Radiomics and Pathomics
  • CRISPR
  • Artificial Intelligence
  • Advancements in Genomics and Personalized Medicine

Chapter 10: Clinical Research in Brain Tumor Therapeutics

  • Introduction
  • The Drug Development Process
    • Drug Discovery
    • Early Formulation Studies
    • Pre-Clinical Safety Studies
    • Clinical Trials
    • Regulatory Review
    • Post-Marketing Surveillance
  • Research Initiatives
    • Defeat GBM Research Collaborative
    • Cancer Moonshot
    • End Brain Cancer Initiative
    • Brain Cancer Translational Research Initiative
    • Pediatric Brain Tumor Initiative
    • GLIOTRAIN
    • GBM Agile
  • Clinical Trials and Experimental Treatments

Chapter 11: Patent Review

  • Introduction
  • Significant Patents

Chapter 12: Competitive Landscape and Market Strategies

  • Introduction
  • Major Players and Market Share Analysis
  • Market Strategies Employed, by Major Players
    • Research and Development
    • Patent Exclusivity
    • Mergers and Acquisitions (M&A)
  • New Developments
  • Porter's Analysis
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat from New Entrants
    • Threat from Substitutes
    • Market Competition

Chapter 13: Regulatory and Reimbursement Landscape

  • Introduction
  • Drug Development Regulations
    • U.S.
    • Canada
    • Mexico
    • Europe
    • Asia Pacific
    • ROW
  • Reimbursement Landscape

Chapter 14: Company Profiles

  • ASTRA ZENECA PLC
    • Business Overview
  • BRISTOL-MYERS SQUIBB CO.
    • Business Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
  • CURTANA PHARMACEUTICALS, INC.
    • Business Overview
  • DEL MAR PHARMACEUTICALS, INC.
    • Business Overview
  • EISAI CO. LTD.
    • Business Overview
  • EMCURE PHARMA
    • Business Overview
  • F. HOFFMANN-LA ROCHE LTD.
    • Business Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
    • Business Highlights
  • FRESENIUS KABI ONCOLOGY LTD.
    • Business Overview
  • IMMUNOCELLULAR THERAPEUTICS LTD.
    • Business Overview
  • ITEOS THERAPEUTICS
    • Business Overview
  • KAZIA THERAPEUTICS LTD.
    • Business Overview
  • MERCK & CO., INC.
    • Business Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
    • Business Highlights
  • NAVINTA LLC
    • Business Overview
  • NEXTSOURCE BIOTECHNOLOGY LLC
    • Business Overview
    • Products and Services
    • Development and Strategies
    • Business Highlights
  • NORTHWEST BIOTHERAPEUTICS, INC.
    • Business Overview
  • NOVARTIS INTERNATIONAL AG
    • Business Overview
    • Financial Information
    • Products and Services
    • Development and Strategies
    • Business Highlights
  • TOCAGEN, INC.
    • Business Overview
  • UNITED THERAPEUTICS CORP.
    • Business Overview

Chapter 15: Appendix: Acronyms

Back to Top
전화 문의
F A Q